We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sensyne Health Plc | LSE:SENS | London | Ordinary Share | GB00BYV3J755 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.35 | 0.30 | 0.40 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSENS
RNS Number : 8349M
Sensyne Health PLC
24 September 2021
Notice of Preliminary Results
Oxford, UK; 24 September 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical clinical AI company, will announce its Preliminary Results for the 12 months ended 30 April 2021 on Friday, 1(st) October.
Lord (Paul) Drayson, Chief Executive Officer, and Richard Pye, Chief Financial Officer, will host a virtual briefing for analysts and investors at 13:00 GMT / 08:00 ET on the day of the results.
Details of the webcast, and the presentation slides, will be available via the Company's website. For more details, please contact CSCSensynehealth@consilium-comms.com.
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058 ) 1845 Lord (Paul) Drayson PhD FREng, Chief Executive Officer Dr Richard Pye, Chief Financial Officer Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418 Broker) 8900 Dr Christopher Golden James Steel Oliver Jackson + 44 (0) 20 3100 Liberum (Joint Broker) 2000 Bidhi Bhoma Euan Brown Consilium Strategic Communications +44 (0) 7780600290 Mary-Jane Elliott Jessica Hodgson Davide Salvi CSCSensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORFZGZLZFFGMZZ
(END) Dow Jones Newswires
September 24, 2021 02:00 ET (06:00 GMT)
1 Year Sensyne Health Chart |
1 Month Sensyne Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions